Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
An insider has filed a Rule 144 notice to sell 709 shares of common stock through broker Merrill Lynch on or about 01/07/2026, to be traded on NASDAQ. These 709 shares were acquired on 01/05/2026 through stock plan activity with the issuer. The notice also lists prior sales over the last three months by the same seller, including 1,396 common shares sold on 01/06/2026 for gross proceeds of 241968, and 27,130 common shares sold on 11/03/2025 for gross proceeds of 4985054. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer.
A company insider filed a Rule 144 notice to sell 2357 shares of common stock through Merrill Lynch on the NASDAQ, with an approximate sale date of 01/07/2026. These 2357 shares of common stock were acquired on 01/05/2026 through stock plan activity from the issuer.
Over the past three months, the same seller, William Lewis, has already sold additional common shares of the issuer. These sales included 4096 shares on 01/06/2026 for gross proceeds of 709959, and two earlier sales of 10699 shares each on 12/18/2025 and 12/04/2025 for gross proceeds of 1786437 and 2199583, respectively.
An insider has filed a notice to sell 1,678 common shares of the issuer through Merrill Lynch on or about 01/07/2026 on the NASDAQ. The filing lists an aggregate market value of 293,935 for these planned sales, compared with 213,273,469 shares outstanding for the issuer.
The shares to be sold were acquired on 01/05/2026 as stock plan activity from the issuer. The notice also discloses that Sara Bonstein sold 1,517 common shares on 01/06/2026, generating gross proceeds of 262,941 over the past three months.
Insmed investor Martina Flammer filed a Form 144 notice indicating an intention to sell 1,434 shares of common stock through Merrill Lynch on the NASDAQ, with an aggregate market value of
As context, the same seller reported prior sales of Insmed common stock over the past three months, including 10,185 shares on
Insmed Inc. filed a notice of proposed insider sale under Rule 144. The filing covers planned sales of 1,517 shares of common stock through Merrill Lynch, with an aggregate market value of $262,941. These shares are part of a class with 213,273,469 shares outstanding and are expected to be sold on or about 01/06/2026 on the NASDAQ exchange. The seller acquired the 1,517 common shares on 01/04/2026 through stock plan activity directly from the issuer, with the payment also dated 01/04/2026 and described as stock plan related ("n/a" for cash nature of payment).
Insmed has a shareholder planning to sell 1,429 shares of its common stock under a Form 144 notice. The sale is expected to be executed through Merrill Lynch in Washington, DC, with an aggregate market value of 247,688 and is targeted for 01/06/2026 on NASDAQ.
The shares to be sold were acquired on 01/04/2026 through stock plan activity from the issuer, with payment made on the same date. The filing also notes that 213,273,469 shares of the issuer’s securities were outstanding, providing context for the planned sale.
Insmed Inc. (INSM) reported a planned sale of company stock under Rule 144. A holder intends to sell 1,396 shares of common stock through Merrill Lynch on or about 01/06/2026 on the NASDAQ market, with an aggregate market value of $241,968.68 based on the figures shown. These shares were acquired from the issuer on 01/04/2026 through stock plan activity, with the same date listed as the payment date.
The notice also reports that during the past three months, Michael Smith sold 27,130 common shares on 11/03/2025 for gross proceeds of $4,985,054. The filing lists 213,273,469 common shares outstanding for the issuer, providing context for the size of the planned transaction.
A shareholder filed a Form 144 indicating an intent to sell 4,096 shares of common stock through Merrill Lynch on or about 01/06/2026, with the stock listed on NASDAQ. These shares were acquired on 01/04/2026 through stock plan activity from the issuer, with the same date listed as the payment date. The filing notes that common shares outstanding were 213,273,469, providing a baseline for the company’s share count.
Over the prior three months, the same seller, William Lewis, reported two additional sales of common stock: 10,699 shares on 12/18/2025 for gross proceeds of 1,786,437, and another 10,699 shares on 12/04/2025 for gross proceeds of 2,199,583. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Insmed’s Chief Legal Officer Michael Alexander Smith received new equity awards. On January 2, 2026, he was granted 5,293 Restricted Stock Units (RSUs), each equal to one share of common stock, under Insmed’s Amended and Restated 2019 Incentive Plan. The RSUs vest 25% on the first day of the first month following the first anniversary of the grant date, then 25% on each anniversary of that initial vesting date until fully vested. The grant increased his directly held common stock to 60,195 shares.
On the same date, he was also granted 27,600 stock options with an exercise price of $177.12 per share, expiring on January 2, 2036. These options vest 25% on the initial vesting date, with an additional 12.5% every six months thereafter until fully exercisable. Following this grant, he holds 27,600 stock options directly.
Insmed Incorporated reported topline results from its Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) and announced that it has discontinued development of brensocatib for this indication. The 24‑week, randomized, double‑blind, placebo‑controlled study enrolled 288 patients across 104 global sites, comparing once‑daily brensocatib 10 mg, brensocatib 40 mg, and placebo, all on top of mometasone furoate nasal spray.
The primary endpoint was change from baseline in the 28‑day average daily Sinus Total Symptom Score at Week 24. Least squares mean changes were -2.44 for placebo, -2.21 for brensocatib 10 mg, and -2.33 for brensocatib 40 mg. Brensocatib was observed to be well tolerated, with similar rates of treatment‑emergent and serious adverse events across arms. Insmed also disclosed it has acquired INS1148, an investigational monoclonal antibody it plans to develop for respiratory, immunological, and inflammatory diseases with high unmet need.